XSHE
300401
Market cap1.23bUSD
Oct 09, Last price
14.65CNY
1D
-3.43%
1Q
-11.53%
Jan 2017
-3.54%
IPO
559.91%
Name
Zhejiang Garden Biopharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Garden Biopharmaceutical Co.,Ltd. operates as a food additive and pharmaceutical manufacturing industry in China. The company provides lanolin cholesterol, vitamin A and AD3 particles, vitamin D3, 25-hydroxyvitamin D3, chemical drugs and Chinese patent medicines. It offers cholesterol; feed grade vitamin D3, refined lanolin; food additives compound nutrient fortifier SDS, CO, and MO; cholecalciferol; feed additive - vitamin D3 particles and oil; VD3 resin oil; 25 hydroxyvitamin D3 progen and powder; 25 hydroxyvitamin D3; anhydrous lanolin; wood oil; wool wax; low chroma pure fat; lanolin alcohol; isopropyl lanolate; lanolinic acid; high acid fat; wood acid biofuel/wood alcohol biofuel; and rodenticide made from Vitamin D3. Zhejiang Garden Biopharmaceutical Co.,Ltd. was formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd. and changed its name to Zhejiang Garden Biopharmaceutical Co.,Ltd. in April 2023. Zhejiang Garden Biopharmaceutical Co.,Ltd. was founded in 2000 and is based in Dongyang, China.
Key people
Huanzheng Ma
Vice Chairman of the Board, General Manager · since 2017
Zhonglan Wei
Vice Chairman of the Board · since 2024
Chunhua Wu
Chief Financial Officer · since 2016
Xiaoping Liu
Deputy General Manager · since 2003
Guoping Qian
Deputy General Manager · since 2024
Xujun Shao
Executive Chairman of the Board · since 2025
Fusheng Fang
Director · since 2024
Jiangang Liu
Executive Deputy General Manager, Director · since 2008
Qinxiang Shao
Director · since 2017
Quanheng Yu
Deputy General Manager, Secretary of the Board, Director · since 2008
Guowei Li
Independent Director · since 2024
Independent Director · since 2021
Qiwei Yang
Independent Director · since 2024
Headquarters & legal address
浙江东阳市南马镇花园村
金华市, ZJ 310000
CN
金华市, ZJ 310000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||